BR112017011591A2 - stable extended release composition, process for preparing the extended release composition - Google Patents

stable extended release composition, process for preparing the extended release composition

Info

Publication number
BR112017011591A2
BR112017011591A2 BR112017011591A BR112017011591A BR112017011591A2 BR 112017011591 A2 BR112017011591 A2 BR 112017011591A2 BR 112017011591 A BR112017011591 A BR 112017011591A BR 112017011591 A BR112017011591 A BR 112017011591A BR 112017011591 A2 BR112017011591 A2 BR 112017011591A2
Authority
BR
Brazil
Prior art keywords
extended release
release composition
composition
preparing
stable
Prior art date
Application number
BR112017011591A
Other languages
Portuguese (pt)
Inventor
Singh Harinder
Kumar KHURANA Lalit
Anand Rachna
Barat Singh Romi
Ahmad Shavej
Kumar Varinder
Sharma Vivek
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of BR112017011591A2 publication Critical patent/BR112017011591A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção se refere a uma composição de liberação prolongada estável de cefpodoxima proxetil e um processo para sua preparação. a composição compreende cefpodoxima proxetil, um estabilizador e um agente de controle de liberação, sendo que a composição é distinguida por ter um ph de menos que cerca de 4. a composição é adequada para dosagem uma vez por dia para tratar infecções bacterianas.The present invention relates to a stable sustained release composition of cefpodoxima proxetil and a process for its preparation. The composition comprises cefpodoxima proxetil, a stabilizer and a release control agent, the composition being distinguished by having a ph of less than about 4. the composition is suitable for once daily dosing to treat bacterial infections.

BR112017011591A 2014-12-01 2015-12-01 stable extended release composition, process for preparing the extended release composition BR112017011591A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3489DE2014 2014-12-01
PCT/IB2015/059254 WO2016088041A1 (en) 2014-12-01 2015-12-01 Extended-release cefpodoxime proxetil composition

Publications (1)

Publication Number Publication Date
BR112017011591A2 true BR112017011591A2 (en) 2018-03-06

Family

ID=56091102

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017011591A BR112017011591A2 (en) 2014-12-01 2015-12-01 stable extended release composition, process for preparing the extended release composition

Country Status (5)

Country Link
BR (1) BR112017011591A2 (en)
MX (1) MX2017007287A (en)
RO (1) RO132297A2 (en)
RU (1) RU2017121505A (en)
WO (1) WO2016088041A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
AU2003260803A1 (en) * 2002-08-30 2004-03-19 Orchid Chemicals And Pharmaceuticals Ltd. Sustained release pharmaceutical composition
EA200702518A1 (en) * 2005-05-16 2008-04-28 Элан Фарма Интернэшнл Лимитед COMPOSITIONS BASED ON NANOPARTICLES AND WITH CONTROLLED SURVIVAL, INCLUDING CEFALOSPORIN
TR201009168A2 (en) * 2010-11-05 2012-05-21 Bi̇lgi̇ç Mahmut Water dispersible cefpodoxime proxetil formulations.
WO2012068076A2 (en) * 2010-11-15 2012-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations containing soluble drugs

Also Published As

Publication number Publication date
RU2017121505A3 (en) 2019-01-09
WO2016088041A1 (en) 2016-06-09
RU2017121505A (en) 2019-01-09
MX2017007287A (en) 2017-08-25
RO132297A2 (en) 2017-12-29
WO2016088041A8 (en) 2017-01-26

Similar Documents

Publication Publication Date Title
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
CL2017001204A1 (en) 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
EA201691988A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
BR112017002221A2 (en) 2- (morpholin-4-yl) -1,7-naphthyridines
BR112016028255A2 (en) immunoregulatory agents
MX2017007299A (en) Gastroretentive extended release suspension compositions.
SG10201909545XA (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
EA201692301A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
BR112015022545A2 (en) pyrazole compounds and the uses thereof
EA201691579A1 (en) DERIVATIVES OF SULFAMOILPYRROLAMIDE AND THEIR APPLICATION AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
BR112017009277A2 (en) silicone compounds
MX2017002954A (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzo xazole.
BR112018005194A2 (en) antifungal compound process
BR112018003864A2 (en) method for preparing a hyaluronic acid composition, composition, and, method for restoring a tissue
BR112017009545A2 (en) antibacterial composition, method for preparing a composition, bacteriophage, isolated nucleic acid, isolated polypeptide, and use of a bacteriophage, nucleic acid or polypeptide
BR112016021282A8 (en) processes for the preparation of antifungal compounds and said compounds
PH12017500533A1 (en) 1-alkyl-6-oxo-1, 6-dihydropyridin-3-yl compounds and use as sgrm modulators
BR112016016853A2 (en) COMPOUNDS CONTAINING NITROGEN, THEIR USE AND THE PREPARATION PROCESS, THE PHARMACEUTICAL COMPOSITION AND THEIR USE
BR112017016084A2 (en) composition and method for the treatment of hepatic veno-occlusive disease
BR112016024096A2 (en) new bacteriophage and composition comprising the same
BR112017011980A2 (en) compound, pharmaceutical composition, and method for treating a bacterial infection.
BR112016028316A2 (en) oral pharmaceutical composition of isotretinoin, its preparation process and treatment method
BR112017006779A2 (en) low dose oral pharmaceutical composition its preparation process and treatment method
EA201690191A1 (en) PHARMACEUTICAL COMPOSITION FOR THE SLOWLY RELEASE OF LANREOTIDE
BR112017026904A2 (en) lefamulin injectable pharmaceutical formulations

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 4A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.